Express News | Bvf Partners LP Reports 8.2% Passive Stake in Verve Therapeutics Inc as of Nov 11 - SEC Filing

BreakingsNov 19 06:31

ARKK's Holdings Ranked by SA Quant Grades

Seeking AlphaNov 13 03:21

CRISPR, Beam, Other Gene Editing Names up Significantly

Seeking AlphaNov 12 02:15

RBC Capital Maintains Verve Therapeutics(VERV.US) With Buy Rating, Cuts Target Price to $17

Futu NewsNov 7 02:32 · Ratings

CCORF Maintains Verve Therapeutics(VERV.US) With Buy Rating, Raises Target Price to $32

Futu NewsNov 7 02:32 · Ratings

J.P. Morgan Maintains Verve Therapeutics(VERV.US) With Hold Rating, Cuts Target Price to $23

Futu NewsNov 7 02:32 · Ratings